BioCatalystWatch
RZLTWorkspace / RZLT / OverviewCompany library
Price
Market cap
Next catalystBy mid-December 2026Ersodetug — upLIFT, tumor hyperinsulinism · Phase 3 dataCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

Ersodetug

Insulin receptor

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Ersodetug

Insulin receptor

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

History / paused

Insulin receptor

PreINDP1P2P3FilingApproved

Plasma kallikrein

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

RZLT SEC archive